Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02193347
Title IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Gary Archer Ph.D.
Indications

malignant glioma

Therapies

Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST